Estrace – is an estrogen drug which has a feminizing body effect, stimulates the development of the vagina, uterus, fallopian tubes, stroma and mammary glands' ducts, pigmentation in the nipples' and genitals' area, formation of secondary female sexual characteristics ( fat redistribution, etc.), growth and closure of epiphyses of long bones. Estrace contributes to a regular rejection of endometrial bleeding, causes endometrial hyperplasia in high concentrations, inhibits bone resorption, induces the synthesis of fibrinogen. Increases blood concentrations of thyroxine, iron, copper, etc.; has procoagulant effect on blood, increases synthesis of vitamin K-dependent coagulation factors (II, VII, IX, X) in the liver, reduces the amount of antithrombin III.
Indications for use:
Estrogen insufficiency in period of menopause and after gynecological operations, ovariotomy, delayed girl's puberty,alopecia provoked by hyperandrogenemia, hirsutism in case of polycystic ovary syndrome, uterine inertia, primary biliary women's cirrhosis, uterine bleedings, postcoital contraception , women's migraine and osteoporosis' prevention in the premenopausal time, men's and women's breast cancer with metastases (palliative therapy) , prostate carcinoma (palliative therapy).
Dosing and Administration: Estrace is taken orally, without chewing, with small water's amount in a dose of 2 mg per day for 21 days, then there is following a break for 7 days, and after that treatment continues again. The treatment duration reaches up to 6 months. Women with a removed uterus or women in postmenopausa, can begin the treatment at any day. When the menstrual cycle is normalized and kept, the reception of first tablet starts with 5 cycle's day (1 cycle day = 1 menstruation's day).